Tamibarotene plus azacitidine for higher-risk myelodysplastic syndrome shows no added benefit in phase 3 trial.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/mds-phase-3-trial-explores-novel-treatment-strategy-2025a1000p60?src=rss
Author :
Publish date : 2025-09-22 13:03:00
Copyright for syndicated content belongs to the linked Source.
